BiotechTube

Montelukast

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Bronchial Asthma

Conditions

Bronchial Asthma, Food Allergy, Children

Trial Timeline

Mar 1, 2013 → May 1, 2016

NCT ID
NCT01618929

About Montelukast

Montelukast is a approved stage product being developed by Merck for Bronchial Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01618929. Target conditions include Bronchial Asthma, Food Allergy, Children.

What happened to similar drugs?

2 of 15 similar drugs in Bronchial Asthma were approved

Approved (2) Terminated (3) Active (10)
✅Formoterol fumerate + fenoterol/ipratropium bromideNovartisApproved
✅Montelukast chewable tablets + Budesonide inhaler + Placebo to montelukast chewable tablets + Placebo to budesonide inhalerOrganonApproved
🔄Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
🔄90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
🔄Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
🔄Test Product + Reference Product + PlaceboAurobindo PharmaPhase 3
❌Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (8)

NCT IDPhaseStatus
NCT01618929ApprovedCompleted
NCT01027806ApprovedTerminated
NCT00492102Phase 1Completed
NCT00559546ApprovedCompleted
NCT00721240ApprovedCompleted
NCT00148603Pre-clinicalCompleted
NCT00934713ApprovedCompleted
NCT00116324Phase 3Completed

Competing Products

20 competing products in Bronchial Asthma

See all competitors
ProductCompanyStageHype Score
TacrolimusAstellas PharmaPhase 2
35
tacrolimusAstellas PharmaPhase 2
35
Albuterol Sulfate Inhalation Aerosol (90 mcg per actuation) + Ventolin HFA 90Mcg/Actuation Inhalation Aerosol_#1 + Ventolin HFA, 90 Mcg/Inh Inhalation Aerosol_#2 + PlaceboCiplaPhase 3
40
90 mcg Reference Product + 180 mcg Reference Product + 90 mcg Test Product + PlaceboCiplaPhase 3
40
Fluticasone propionate/salmeterol 100/50 µg + Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUATCiplaPhase 3
40
Test Product + Reference Product + PlaceboAurobindo PharmaPhase 3
40
Albuterol Sulfate HFA 0.09 mg (Reference) + Albuterol Sulfate HFA 0.18 mg (Reference) + Albuterol Sulfate HFA 0.09 mg (Test) + Albuterol Sulfate HFA 0.18 mg (Test) + PlaceboAurobindo PharmaPhase 3
32
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerGlenmark PharmaceuticalsPhase 3
36
Symbicort Turbuhaler + Symbicort pMDI + Pulmicort TurbuhalerAstraZenecaPhase 3
40
RoflumilastAstraZenecaPhase 3
40
RoflumilastAstraZenecaPhase 2/3
38
Symbicort (budesonide/formoterol) Turbuhaler + Conventional treatmentAstraZenecaPhase 3
32
CiclesonideAstraZenecaPhase 3
40
Montelukast plus prednisolone + PrednisoloneMerckPhase 2
35
Formoterol fumerate + fenoterol/ipratropium bromideNovartisApproved
43
inhaled corticosteroid therapyNovartisPhase 1/2
32
PF-00610355 + PF - 00610355 + PF - 00610355PfizerPhase 2
27
NivolumabBristol Myers SquibbPhase 2
39
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
42
HSK31858 + PlaceboHaisco Pharmaceutical GroupPhase 2
42